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ABSTRACT
The past decade has seen significant advances in the understanding of molecular pathogenesis of cutaneous 
melanoma. Currently, mutations of BRAF oncogene have been a well established and powerful predictive role as 
validated target in recently developed molecular targeted therapy for melanoma. It has been proven in a number 
of studies that the effective treatment for this group of patients consists of the combination of a BRAF inhibitor 
and MEK inhibitor, two such combinations are currently registered and reimbursed in Poland — vemurafenib and 
cobimetinib, dabrafenib and trametinib. Median progression-free survival (PFS) exceeds one year for BRAF and 
MEK combined therapy, and overall survival (OS) reaches approximately 2 years. Currently, the first line therapeutic 
option for BRAF-mutated advanced melanoma include also immunotherapy with anti-PD-1 antibodies (combination 
of PD-1/CTLA-4 blockers can be an option in a specific group of patients, although not reimbursed in Poland).
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Introduction
Melanoma is a cancer that in Poland has the most 
dynamic growth in the number of cases — in the years 
1982–2012 the number of new cases increased almost 
three-fold. Standardised mortality rates reach ap-
proximately 2.33/100,000 in men and 1.53/100,000 in 
women, which corresponds to approximately 7600 and 
6350 deaths, respectively, from melanoma in recent 
years, and the number of new cases in 2014 exceeded 
1600 in women and was about 1500 in men [1–3]. 
It is now known that certain melanoma subtypes are 
associated with specific mutations. BRAF mutations 
(v-raf murine sarcoma viral oncogene homolog B1) 
and NRAS [neuroblastoma RAS viral (v-ras) oncogene 
homolog] occur in 40–60% and 10–20% of skin melano-
mas, respectively. In most cases, the occurrence of these 
mutations is mutually exclusive. RAS/RAF/MEK/ERK 
over-expression and transmitting signals to growth factor 
receptors has been shown to play a major role in regu-
lating cell proliferation, tumour invasion, and survival 
in the cells of the majority of melanomas [4–9]. This is 
most often due to the presence of mutations that activate 
the individual components of this pathway, in more than 
half of melanomas — the BRAF gene [5, 6]. The most 
common BRAF mutation — p.V600E (74–90%) — is 
a point mutation of the sense-change type caused by 
the substitution of valine (V) by glutamic acid (E) at 
position 600 of exon 15 (1799) [5, 10–13]. Substitution 
of V600E results in a 500-fold increase in BRAF kinase 
activity compared to normal (wild-type) BRAF [12]. It 
is mainly found in non-chronic sun damage (NCSD) [7] 
and in younger age as well as in a high percentage of 
benign skin pigmentation, but not in ocular melanoma 
and only in 10% of melanomas occurring on mucous 
membranes and areas exposed to direct sunlight (CSD, 
chronic sun damaged). 
The less frequent mutation p.V600K (16–29%) is 
characterised by valine substitution (V) by lysine (K) 
[15–17]. BRAF V600E results in constitutive activation 
of the ERK signalling pathway, resulting in stimulation 
of cell proliferation and tumour mass gain. BRAF V600E 
also has implications for tumour neoangiogenesis by 
stimulating vascular endothelial growth factor (VEGF) 
[18]. Without a doubt, mutant BRAF is important in 
the process of melanoma, but the presence of the same 
mutation BRAF V600E is not sufficient for the trans-
formation of melanocytes in the direction of malignancy 
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[19, 20]. It is worth noting that the BRAF mutation is 
found in most benign pigmented moles (80%) [21, 22], 
which in rare cases undergo malignant transformation. 
In the development of melanoma, additional molecular 
disorders are necessary [22, 23]. Accurate knowledge 
of the role of BRAF mutation in the pathogenesis of 
melanoma had a strong impact on the development of 
further drug research targeted on a molecular level; 
the first effective molecularly targeted drug in patients 
with advanced melanoma with the presence of BRAF 
mutation was vemurafenib. Currently, inhibitors of 
BRAF are used routinely in combination with inhibi-
tors of MEK, now these drugs are tested in the adjuvant 
treatment and in combination or sequentially with im-
munotherapy.
In patients with metastatic (primary or secondary) 
skin melanomas, it is mandatory to check the presence 
of BRAF mutation in fixed material [it may be also justi-
fied in cases with high risk of relapse (stage IIIB, IIIC, 
and IIID)]. The assessment of the mutations in KIT 
and NRAS genes is optional. No additional biopsies are 
needed to verify the presence of molecular abnormali-
ties within the metastatic lesions [2, 24].
A breakthrough in the treatment of systemic mela-
noma has taken place within the last five years, which 
is associated both with the development of molecular 
targeted therapies and immunotherapy [1, 2, 24, 25]. 
New therapies introduced into everyday clinical practice 
applied in cases of unresectable/metastatic melanoma 
skin have little to do with clinical practice five years ago. 
In the last five years in Europe vemurafenib, dabrafenib, 
trametinib, cobimetinib, ipilimumab, nivolumab, pem-
brolizumab, and Talimogene Laherparepvec (T-VEC) 
were registered [1, 2, 24, 25]. Currently, seven new 
therapies are available in Poland — vemurafenib with 
cobimetinib, dabrafenib with trametinib, ipilimumab, 
pembrolizumab, and nivolumab. Unfortunately, their 
full reimbursement indications continue to differ from 
those used in Western Europe and the United States.
Currently, the basis of systemic treatment is com-
bination therapy with molecular-targeted drugs and 
immunotherapy. Moreover, the latest data also provide 
hope for progress in the adjuvant treatment of patients 
at high risk of relapse.
Molecularly targeted therapy
Phase II–III studies demonstrated median survival 
in patients with metastatic melanoma treated with 
vemurafenib or dabrafenib of 13–18 months (similar 
in approximately 180 patients treated in our country 
with vemurafenib as routine clinical practice), which 
is significantly higher than previously observed in this 
group of patients [1]. 
Results of the coBRIM study, in which vemu-
rafenib or vemurafenib with cobimetinib was used, 
confirmed that BRAF and MEK combination therapy 
in BRAF-positive metastatic melanoma patients was 
superior to monotherapy with no increase in toxicity: 
progression-free survival was 7.20 vs. 12.3 months (HR 
95% CI: 0.58), CR (complete response) was 10.5% and 
15.8%, respectively. The median overall survival (OS) 
was 22.3 months for the combination treatment as 
compared to 17.4 months for monotherapy (p = 0.005) 
[26]. Long-term results from the Phase 1b BRIM7 on 
the use of combination therapy with vemurafenib and 
cobimetinib in those treated (V-PD) or untreated (naive 
BRAFi) previously with vemurafenib showed median 
PFS in the group BRAFi-naive of 13.8 months and me-
dian OS of 31.2 months (three-year OS was 37%) [27]. 
Recent study results (COMBI-d and COMBI-v) 
showed that median overall survival (OS) with the 
combination of these drugs has increased to approx. 
25 months (approximately two years), while three years 
ago the OS for metastatic patients was six months. The 
combined use of dabrafenib and trametinib resulted 
in the two-year overall survival of 51%, with the use 
of only a single drug being about 10% lower. The 
median time to progression of disease in patients 
treated with dabrafenib and trametinib was 11 months 
and was significantly higher than that for dabrafenib 
alone (8.8 months). Objective responses (partial and 
total responses) were 70% vs. 50%, respectively. Up-
dated results of the COMBI-d were: the percentage of 
three-year OS was 44% in patients treated with dab-
rafenib and trametinib and 32% in the monotherapy 
group with dabrafenib. Three-year progression-free 
survival (PFS) was, respectively, 22% and 12% [28–30]. 
The best results were obtained in patients with normal 
levels of LDH and with no more than three metastatic 
sites. Another combination of BRAF (encorafenib, 
ENCO) and MEK (binimetinib, BINI) inhibitors was 
also evaluated in the Ib/II phase III study in patients 
with advanced melanoma with BRAFV600 mutation. 
The percentage of confirmed responses was 72–78%. 
The median progression-free survival in patients with 
elevated lactate dehydrogenase (LDH) was 6.8 months, 
and in the group with normal LDH — 20 months. Tolera - 
bility of treatment was good, and similar results were 
obtained in Phase III study [31].
A new option for targeted treatment is to return to 
the combination of BRAF and MEK inhibitors after 
prior discontinuation due to progression. A phase II 
study demonstrated that in eight out of 25 patients 
(32%) partial remission of the disease was obtained by 
re-initiation of therapy with dabrafenib and trametinib, 
and stable disease in another 40%; median PFS on 
the so-called rechallenge was 4.9 months. During the 
2017 ASCO congress 116 patients were analysed with 
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Table 1. Registered molecularly targeted drugs for the treatment of patients with advanced melanoma with the presence 
of BRAF mutations used in the context of drug programs in Poland
Name  
of the drug
Registration/ 
/Clinical trials
Efficacy Adverse events/remarks
Vemurafenib  
(BRAF inhibitor) 
alone or in 
combination 
with cobimetinib 
(MEK inhibitor)
Registered in Europe 
and the USA in patients 
with a mutation in the 
BRAF gene
Median OS: 17 months (22.3 months for 
combined treatment)  
Median PFS: 5.3–7.2 months 
(12.3 months for combination therapy 
with cobimetinib); ORR — 48%  
Median time to obtain response: 
1.4 months
Typical side effects include: arthralgia, 
rash, fatigue, photosensitivity, and 
development of squamous cell carcinoma 
or keratoacanthoma (skin-related adverse 
events are significantly less frequent 
when combined with cobimetinib). 
Quick response. Demonstrated activity in 
patients with brain metastases
Dabrafenib  
(BRAF inhibitor) 
in monotherapy 
or in combination 
with trametinib 
(MEK inhibitor)
Registered in Europe 
and the USA in patients 
with a mutation in the 
BRAF gene
Median OS: 18.2 months (25.1– 
–25.6 months in combination with 
trametinib) 2-year OS (in combination 
treatment: 51–52%, 3-year: 44%
Median PFS: 5.1–8.8 months in 
monotherapy (11–11.4 months in 
combination), 2-year PFS for combined 
treatment 30%, 3-year 22%.
Percentage of responses: 54% in 
monotherapy or 64–69% in combination 
therapy
Typical side effects include: skin toxicity, 
fever, arthralgia, fatigue; reduction of 
skin toxicity with combination therapy 
(but with the occurrence of adverse 
events associated with MEK inhibitors). 
Quick response. Demonstrated activity in 
patients with untreated brain metastases
Trametinib 
(MEK inhibitor)
Registered in the USA 
(in combination with 
dabrafenib) and in 
Europe (monotherapy) 
in patients with 
a demonstrated mutation 
in the BRAF gene
Median PFS: 4.8 months;
6-month survival rate: 81%
Common side effects: rash, diarrhoea, 
peripheral oedema. Monotherapy 
has lower activity than BRAF 
inhibitors. Currently used in combination 
with dabrafenib. Activity in melanoma 
patients with the presence of NRAS 
mutations has also been demonstrated
OS — overall survival; PFS — progression-free survival; ORR — objective response rate
advanced melanoma, who were treated with a BRAF 
inhibitor and after the break in the therapy (due to 
progression) again received treatment with BRAF 
+/– MEK inhibitor. The median duration of treat-
ment with BRAFi +/– MEKi inhibitor the first time 
was 9.4 months and then 7.7 months upon return to 
targeted molecular therapy. On return to treatment with 
BRAFi +/– MEKi, the response rate was 43%: total 
response (CR) 3%, partial response (PR) 39%, disease 
stabilisation 24%, disease progression (PD) 30%, and 
4% no data. The median overall survival from onset of 
re-treatment was 9.8 months [32, 33].
A summary of the results of use of molecular tar-
geted therapy in patients with advanced melanoma with 
the presence of BRAF mutations is shown in Table 1.
Preliminary results of the analysis of the Polish drug 
programs in the treatment of advanced melanoma with 
the presence of BRAF mutation using vemurafenib with 
cobimetinib or dabrafenib with trametinib presented at 
the Warsaw Skin Cancer Conference in 2017 showed an 
annual survival rate of 70%, which is comparable to the 
results obtained from clinical trials. There was no dif-
ference in OS between the combination of vemurafenib 
and cobimetinib and dabrafenib with trametinib [34].
Use of molecularly targeted therapy BRAF inhibi-
tors of MEK and as adjuvant treatment after resection 
of lymph nodes improves disease-free survival and 
overall survival, but their definitive place in an adjuvant 
setting involves assessment of the full results of the 
clinical trials [35].
Immunotherapy
Non-specific immunotherapy (mainly with an-
ti-CTLA4 monoclonal antibodies — ipilimumab and 
anti-PD-1 — nivolumab and pembrolizumab) also led to 
a significant improvement in the treatment of patients 
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Table 2. Comparison of treatment with BRAF +/– MEK inhibitors and immunotherapy with checkpoint inhibitors
Feature Targeted treatment Immunotherapy with anti-PD-1
Dosage 
schedule 
Continuous daily orally IV every 2–3 weeks
Safety (AE) Grade 3/4 events in 35–52% of patients receiving 
BRAF + MEK inhibitor 
Dose reduction in about 1/4 of patients and cessation 
of therapy due to intolerance in 9–13%
Grade 3/4 AE incidence in 8–16% and discontinuation of 
therapy due to AE in 2–9%
Objective 
responses
ORR 64–67% ORR in about 40% with anti-PD-1; ORR 43–62% with the 
anti-PD-1/anti-CTLA-4 combination (38–52% with BRAF+)
Survival Median OS 25 months and a 2-year OS of 51%; 
unknown durability of response (especially after 
discontinuation of therapy)
Median OS 17–31 months; 2-year OS 57–60%; long-lasting 
responses; persistence of response after discontinuation of 
therapy; 2-year OS for anti-PD-1/anti-CTLA-4 64–79%
with metastatic melanoma. There are no definitive data 
on the sequence of the use of immunotherapy and mole-
cular-targeted treatment in patients with BRAF-positive 
melanomas, although the activity of BRAF inhibitors is 
preserved after immunotherapy, as is the efficacy of im-
munotherapy (anti-PD-1) after treatment with inhibitors.
At the moment, the weight of the treatment of 
advanced melanoma using immunotherapy has moved 
towards the treatment of anti-PD-1 (nivolumab or 
pembrolizumab) acting on the control points of the im-
mune system (as receptor PD-1 and its ligand PD-L1) 
and stimulating T-lymphocyte function mainly by 
blocking negative signalling molecules for their activa-
tion, or by implementing combination therapy with 
anti-CTLA-4 and anti-PD-1 antibodies (taking into 
account the greater toxicity and cost of this drug com-
bination). These drugs have demonstrated in a clinical 
setting, either in monotherapy or in combination with 
ipilimumab, long-term clinical benefit in some patients 
with advanced melanomas and significant response rates 
(up to 50%), with annual survival of 70–80% and less 
toxicity than ipilimumab [36–38].
Summary
In the case of BRAF mutation in a patient with meta-
static melanoma, the molecularly targeted therapy of 
choice is the combination of MEK inhibitor and BRAF 
in the first — or second-line therapy, or immunotherapy 
(Tab. 2, Fig. 1).
In summary, anti-PD-1 antibodies and combined 
treatment with BRAF and MEK inhibitors are 
endorsed both by Polish, European (ESMO), and 
American (NCCN) recommendations as a standard 
therapeutic option with proven efficacy in the treat-
ment of advanced melanomas [1, 2, 24, 25]. For both 
pembrolizumab/nivolumab and combination therapy of 
the BRAF and MEK inhibitor, in the group of patients 
with metastatic melanoma with the presence of the 
BRAF mutation, the median OS from clinical trials is 
currently about two years (about four times longer than 
five years ago). It is not definitively known whether to 
start treatment in this group with immunotherapy or 
molecular-targeted drugs, hence the need to leave the 
decision for the treatment team. As part of existing 
drug programs in Poland, there is now the possibility 
of choosing the first line of therapy in patients with 
BRAF mutation — treatment for immunotherapy 
or treatment with BRAF + MEK inhibitors may be 
started and alternative therapy may be used if possible 
progression. Because BRAF inhibitors (+ MEK inhibi-
tors) in patients with advanced BRAF mutations cause 
rapid response and tumour control in the majority of 
patients, with limited response time associated with 
the activation of resistance mechanisms, these drugs 
should always be considered as the choice of treatment 
in patients with symptoms of the disease and/or high 
tumour mass. 
Figure 1 shows the current therapeutic regimen for 
patients with advanced melanoma with the presence 
of BRAF mutation.
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Figure 1. Scheme of therapeutic treatment in patients with advanced melanoma with BRAF mutation
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